Why the Same Coffee Can Feel Completely Different

What twin studies actually measure

Classical twin studies compare how similar monozygotic twins are with how similar dizygotic twins are. If identical pairs resemble one another more for a measured trait, genetic differences may explain part of the variation in that population. The estimate depends on the people, culture, measurement, age and available environments.

This is why 'caffeine is 36-58% genetic' is too loose. Earlier reviews reported heritability estimates in roughly that range for several caffeine-related traits. But the traits were not identical: use, heavy use, tolerance, withdrawal, intoxication and sleep disturbance are different outcomes.

The population matters too. In a large Australian sample, patterns differed between tea and coffee and between men and women. In 1,106 Korean twins studied in research published in July 2026, heritability was estimated at 29% for coffee-drinking status, 11% for tea drinking and 27% for total caffeine intake. Unique environmental factors explained the majority. When the Korean researchers used a different threshold for regular coffee drinking, the estimate changed to 50%. That is not a contradiction. It is a demonstration that heritability belongs to the definition and population, not to caffeine as a universal constant.

Three questions that are often mixed together

or consume more caffeine?

clear caffeine?

given exposure?

Twin studies are especially useful for the first question and for broad individual differences. Molecular and experimental studies help address the second and third. A responsible article must not label every finding 'twin research' simply because the topics are connected.

• Consumption: Are some people more genetically inclined to drink coffee
• Pharmacokinetics: How quickly does the body absorb, transform and
• Pharmacodynamics: How strongly do the brain and body respond at a

CYP1A2: an important part of the metabolic story

CYP1A2 is a liver enzyme that plays a major role in caffeine metabolism. Genome-wide research in 47,341 people identified strong associations near AHR and the CYP1A1-CYP1A2 region with habitual caffeine consumption. AHR regulates CYP1A2, linking intake behavior to a biologically plausible metabolic pathway.

An influential laboratory study using human CYP enzymes expressed in cells found that CYP1A2 converted caffeine predominantly to paraxanthine, with smaller pathways to theobromine and theophylline: about 81.5%, 10.8% and 5.4%, respectively. Those percentages describe that experimental system, not a guaranteed breakdown for every person after every cup. They are useful for teaching the pathway, provided the context is stated.

mainly paraxanthine, plus smaller amounts of theobromine and theophylline. Genetic variation and environmental enzyme modifiers can change the speed and pattern of exposure.

Genotype is not the only switch. Smoking can induce CYP1A2 activity, while estrogen-containing contraceptives can reduce caffeine clearance. Pregnancy, medicines, liver function and other factors may also matter. A 2016 twin study of caffeine pharmacokinetics concluded that environmental factors such as smoking and hormonal contraceptives can mask genetic effects. The clean 'fast versus slow metabolizer' label is therefore often less precise than commercial genetic reports suggest.

ADORA2A: how the brain receives the signal

Caffeine promotes alertness mainly by antagonizing adenosine receptors. ADORA2A encodes the adenosine A2A receptor, an important part of that pathway. Variants in and around ADORA2A have been associated with differences in caffeine-related anxiety, sleep effects, habitual intake and performance under sleep loss.

In a controlled experiment involving prolonged wakefulness, researchers tested 82 volunteers genetically and studied stimulant responses in a subgroup of 45 young men. ADORA2A haplotypes were linked to differences in vigilance and to whether caffeine counteracted performance impairment and changes in recovery-sleep EEG. This is intriguing mechanistic evidence, but the small and selective sample means it should not be turned into a universal genotype prescription.

A useful correction from theophylline twin research

Theophylline is a related methylxanthine and a minor caffeine metabolite. A 1984 pharmacokinetic study included 13 monozygotic pairs, 11 dizygotic pairs and six single participants. Identical twins tended to resemble each other more, but most mean differences between monozygotic and dizygotic pairs were not statistically significant. The authors described a smaller genetic contribution than had been reported for several other drugs.

That nuance matters. It is fair to say the study investigated genetic control of theophylline metabolism and found suggestive family patterns. It is not fair to present it as decisive proof that metabolism is strongly genetic for everyone.

What this means in everyday life

The most practical conclusion is not to buy a gene test and let one variant dictate your behavior. It is to treat your response as measurable and personal. If caffeine improves a morning workout but delays sleep, both effects belong in the decision. If two twins respond differently, that difference is data - not evidence that one has stronger willpower.

cups.

next-day alertness.

response when relevant.

several comparable days.

only what both people consent to share.

• Track the actual source and estimated dose, not only the number of
• Record the time of the final caffeine dose and the intended bedtime.
• Follow sleep onset, awakenings, total sleep, perceived recovery and
• Note anxiety, palpitations, gastrointestinal effects and workout
• Change one major variable at a time and repeat the observation across
• If comparing with a twin or partner, agree on the protocol and share

Explore with TwinPare

Follow your own pattern instead of chasing somebody else's ideal dose. TwinPare Health & Fitness is designed around baselines, trends and consent-based comparison. \[Insert approved app or waitlist CTA.\]

Sources and methodology

Twin, genomic, pharmacokinetic and controlled experimental evidence were kept as separate evidence types. Source review date: 17 August 2026.